(Sharecast News) - Drugmaker AstraZeneca said on Thursday that Tezspire had delivered positive Phase III results in eosinophilic oesophagitis (EoE), hitting both co‑primary endpoints and all key secondary measures, with improvements sustained through 52 weeks.
AstraZeneca said the CROSSING study showed Tezspire produced "statistically significant and clinically meaningful" gains in histologic...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE